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Abstract
Background: Adipose tissue is a key regulator of energy balance playing an active role in lipid storage and may
be a dynamic buffer to control fatty acid flux. Just like PPARg, fatty acid synthesis enzymes such as FASN have
been implicated in almost all aspects of human metabolic alterations such as obesity, insulin resistance or
dyslipemia. The aim of this work is to investigate how FASN and PPARg expression in human adipose tissue is
related to carbohydrate metabolism dysfunction and obesity.
Methods: The study included eighty-seven patients which were classified according to their BMI and to their
glycaemia levels in order to study FASN and PPARg gene expression levels, anthropometric and biochemical
variables.
Results: The main result of this work is the close relation between FASN expression level and the factors that lead
to hyperglycemic state (increased values of glucose levels, HOMA-IR, HbA1c, BMI and triglycerides). The correlation
of the enzyme with these parameters is inversely proportional. On the other hand, PPARg is not related to
carbohydrate metabolism.
Conclusions: We can demonstrate that FASN expression is a good candidate to study the pathophysiology of type
II diabetes and obesity in humans.
Background
Adipose tissue is recognized as a key regulator of energy
balance, playing an active role in lipid storage with mul-
tiple distinct deposits (subcutaneous, intra-abdominal
and intrathoracic) [1]. Indeed, adipocytes of visceral
abdominal fat origin are more endocrinologically active
than the subcutaneous variety [2]. In addition, adipose
tissue can buffer, synthesize and secrete a wide range of
endocrinal products into circulating blood that is influ-
ential on the systemic metabolism and may be directly
involved in the pathogenesis of associated complications
such as obesity, diabetes, vascular damage and athero-
sclerosis [1,3]. Thus, adipose tissue may serve as a
dynamic buffer to control fatty acid (FA) flux in
response to changing energy demands: in the fasting
state, adipose tissue releases FAs, whereas in the fed
state, adipocytes change to “absorb” FAs from the circu-
lation, mainly from circulating triglycerides (TG) [4,5].
This function is known to be altered in obese subjects
with metabolic syndrome features (insulin resistance,
obesity, dyslipemia, inflammation, atherosclerosis and
hypertension) [6,7].
The nuclear receptor peroxisome proliferator-activated
receptor gamma (PPARg) is a ligand-activated transcrip-
tion factor, member of the nuclear hormone receptor
superfamily, which functions as a heterodimer with a
retinoid X receptor (RXR) [8]. The actions of PPARg are
mediated by two protein isoforms which are derived
from the same gene by alternative promoter usage and
splicing: the widely expressed PPARg1 and the adipose
tissue-restricted PPARg2 [9]. The activation of PPARg
leads to adipocyte differentiation and fatty-acid storage,
whereas it represses genes that induce lipolysis and the
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Authors have shown that the loss-of-function mutation
of PPARg results in severe insulin resistance and causes
elevated TG and decreased high density lipoprotein-cho-
lesterol levels in humans while increased PPARg activity
enhances insulin sensitivity and improves dyslipidemia
in insulin-resistant individuals [11].
PPARg transcriptionally regulates many genes involved
in metabolism [12], even those involved in the synthesis
of FAs. There are two sources of FA, exogenously-
derived (dietary) and endogenously-synthesized FA, both
are essential constituents of biological membrane lipids
and important substrates for energy metabolism. The
biosynthesis of the latter is catalysed by Fatty Acid
Synthase (FASN) and Acetyl-CoA Carboxylase (ACC),
key enzymes of lipogenesis that may play a crucial role
in the weight variability of abdominal adipose tissue
[13]. Specifically, FASN (EC 2.3.1.85) is a multifunc-
tional enzymatic complex, important in the regulation
of body weight and the development of obesity [13-15]
and necessary for de novo synthesis of long-chain satu-
rated FAs from acetyl coenzyme A (CoA), malonyl-CoA
and NADPH. The expression of this enzyme is highly
dependent on nutritional conditions in lipogenic tissues.
FASN-catalysed endogenous FA biosynthesis in liver
and adipose tissue is stimulated by a high carbohydrate
diet, whereas it is suppressed by the presence of small
amounts of FA in the diet and by fasting [16].
There are several studies that connect FASN activity/
expression with metabolic alterations in humans such as
obesity, dyslipemia, insulin resistance and altered adipo-
cytokine serum profile [17]. Although there are authors
that have shown how FASN gene expression is signifi-
cantly higher in obese vs lean individuals [17-19], there
are studies that found the way in which FASN mRNA
expression was decreased in the subcutaneous adipose
tissue of obese vs lean individuals [20]. Divergent find-
ings may be explained by differences in metabolic para-
meters and the size of the study population. We
contribute to study the role of FASN with a general
population with a wide range of body mass index (BMI)
and metabolic parameters, in order to clarify the asso-
ciation between FASN activity/expression, the grade of
insulin resistance and obesity-related insulin resistance.
Methods
Experimental subjects
The study included 87 healthy persons (35 men and 52
women) who underwent laparoscopic surgery proce-
dures (hiatus hernia repair or cholecystectomies).
Patients were classified into three groups according to
BMI: normal (BMI < 25), overweight (25 ≤ BMI < 30)
and obese (BMI ≥ 30). Patients were also classified into
normoglycemic (no diabetes antecedents and glucose
levels in a fast state ≤ 110 mg/dl) and hyperglycemic
(diabetics or people with basal glycaemia values in a fast
state >110 mg/dl) groups. This study was approved by
the Hospital’s Ethical Committee and all participants
signed their consent after being fully informed of its
goal and characteristics.
Study design
Before surgery and after an overnight fast, the patient’s
height and weight was measured to calculate the BMI and
the waist and circumference to calculate the waist to hip
ratio (W-H). In addition, systolic blood pressure (SBP) and
diastolic blood pressure (DBP) were noted. During surgical
intervention, biopsies of visceral adipose tissue were
immediately frozen in liquid nitrogen and stored at -80°C
for gene expression analysis. Blood samples were collected;
serum and plasma were separated in aliquots within 30
min of extraction, and immediately frozen at -80°C.
Biochemical variables were: glucose, cholesterol, TG,
high density lipoprotein-cholesterol (HDL-c) and low
density lipoprotein-cholesterol (LDL-c), glycated haemo-
globin (HbA1c), C-reactive protein (CRP) and all were
measured in a Dimension Autoanalyzer (Dade Behring,
Deerfield, IL) in duplicate. Serum insulin concentration
was analyzed by an immunoradiometric assay (IRMA)
(BioSource International, Camarillo, CA). Leptin and
adiponectin were analysed by enzyme immunoassay
(ELISA) kits (Mediagnost, Reutlingen, Germany and
DRG Diagnostics GmbH, Germany, respectively). The
homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated as follows: fasting glucose
(mg/dl) * fasting insulin (uU/ml)/405 [21].
RNA extraction and real time quantitative PCR: Adi-
pose tissue RNA isolation was performed by homogeni-
zation with an ULTRATURRAX T25 basic (IKA Werke
GmbH, Staufen, Germany) using Trizol reagent (Invitro-
gen, Barcelona, Spain). Samples were purified using
RNAEasy Mini kit (QIAGEN, Barcelona, Spain) and
treated with DNase (RNase-free DNase Set, Qiagen). For
first strand cDNA synthesis, constant amounts of 1 μg
of total RNA were reverse transcribed using random
hexamers as primers and Transcriptor Reverse Tran-
scriptase (Roche, Mannheim, Germany). Gene expres-
sion was assessed by real time PCR using an ABI Prism
7000 Sequence Detection System (Applied Biosystems,
Darmstadt, Germany), using TaqMan® technology suita-
ble for relative genetic FASN expression quantification.
The reaction was performed, following the manufac-
turers protocol, in a final volume of 25 μl. The cycle
program consisted of an initial denaturing of 10 min at
95°C, followed by 40 15 sec denaturizing phase cycles at
95°C and a 1 min annealing and extension phase at 60°
C. Commercially available and pre-validated TaqMan®
primer/probe sets were used as follows: PPIA (4333763,
RefSeq. NM_002046.3, Cyclophilin A (PPIA), used as
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and FASN (Hs00188012_m1, RefSeq. NM_004104.4,
Fatty Acid Synthase). A threshold cycle (Ct value) was
obtained for each amplification curve and a ΔCt value
was first calculated by subtracting the Ct value for
human PPIA cDNA from the Ct value for each sample
and transcript. Fold changes compared with the
endogenous control were then determined by calculating
2
-ΔCt, so FASN expression results are expressed as the
expression ratio relative to PPIA gene expression
according to the manufacturer’s guidelines. The tran-
script levels of nuclear receptors PPARg1a n dP P A R g2
were quantified by real-time reverse transcription RT-
PCR, using LightCycler® technology (Roche Diagnostic,
Rotkreuz, Switzerland) with SYBR Green detection. The
primers for the PCR reaction (Sigma Proligo) were: a
common reverse primer for PPARg1a n df o rP P A R g2,
CTTCCATTACCGAGAGATCC. The forward primer
for PPARg1 was AAAGAAGGCGACAACTAAACC and
GCGATTCCTTCACTGATAC for PPARg2. A standard
Table 1 Anthropometrical and biochemical characteristics of study subjects: normal, overweight and obese individuals
Means SD P Means SD P
BMI
Normal 22.453 2.317
0.00 TG
Normal 83.353 32.017 0.00
Overweight 27.389 1.563 Overweight 141.600 81.945
Obese 34.393 3.801 Obese 141.286 63.364
Total 26.554 4.856 Total 117.687 68.273
SBP
Normal 121.543 20.860
0.00 LDL-c
Normal 123.294 28.510 0.88
Overweight 131.114 15.854 Overweight 122.229 28.823
Obese 140.857 17.110 Obese 126.857 26.921
Total 128.750 19.392 Total 123.446 28.091
DBP
Normal 75.086 12.344
0.25 HDL-c
Normal 55.853 15.182 0.30
Overweight 76.857 10.097 Overweight 51.800 12.211
Obese 80.714 6.390 Obese 50.286 9.659
Total 76.762 10.696 Total 53.205 13.213
W-H ratio
Normal 0.862 0.080
0.02 CRP
Normal 5.285 17.498 0.16
Overweight 0.897 0.068 Overweight 3.254 2.576
Obese 0.930 0.093 Obese 11.143 14.854
Total 0.888 0.081 Total 5.417 12.983
Insulin
Normal 10.824 6.162
0.11 Adiponectin
Normal 23.423 14.405 0.00
Overweight 13.537 6.134 Overweight 13.794 5.904
Obese 14.736 7.938 Obese 16.963 6.891
Total 12.685 6.593 Total 18.190 11.087
Glycaemia
Normal 79.735 8.972
0.01 Leptin
Normal 12.005 14.011 0.00
Overweight 100.200 37.802 Overweight 18.745 16.660
Obese 93.857 11.455 Obese 33.039 22.406
Total 90.747 27.125 Total 18.730 18.300
HbA1c
Normal 5.509 0.330
0.00 FASN
Normal 0.316 0.179 0.00
Overweight 5.829 0.688 Overweight 0.194 0.151
Obese 6.064 0.472 Obese 0.127 0.100
Total 5.737 0.565 Total 0.237 0.172
HOMA-IR
Normal 2.129 1.103
0.00 PPARg1
Normal 0.031 0.048 0.39
Overweight 3.373 1.911 Overweight 0.086 0.232
Obese 3.639 2.201 Obese 0.100 0.267
Total 2.914 1.787 Total 0.063 0.181
Cholesterol
Normal 199.529 39.368
0.96 PPARg2
Normal 0.006 0.004 0.36
Overweight 200.543 36.575 Overweight 0.007 0.005
Obese 202.786 33.971 Obese 0.005 0.003
Total 200.506 36.914 Total 0.007 0.004
Values are presented as means ± SD. BMI, body mass index (Kg/m
2); SBP, systolic blood pressure (mm Hg); DBP, diastolic blood pressure (mm Hg); W-H ratio,
waist to hip ratio; Insulin (UI/ml); Glycaemia (mg/dl); HbA1c, glycated haemoglobin (%); HOMA-IR, homeostasis model assessment ((gluc mg/dl*insul U/ml)/405);
Cholesterol (mg/dl); TG, triglycerides (mg/dl); LDL-c, low density lipoprotein-cholesterol (mg/dl); HDL-c, high density lipoprotein-cholesterol (mg/dl); CRP, c-
reactive protein (mg/l); Adiponectin (ng/ml); Leptin (ng/ml); FASN, fatty acid synthase; PPARg, peroxisome proliferator-activated receptor.
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ment from human adipose tissue total RNA (Clontech
Laboratories, Inc., Mountain View, CA). For quantifica-
tion purposes, PPARg mRNA levels were always
reported to the levels of b-actin, constitutively expressed
gene. Primers for b-actin were AACTGGAACGGT-
GAAGGTGAC as forward and TGTGGACTTGGGA-
GAGGACTG as reverse. All samples were quantified in
duplicate and positive and negative controls were
included in all the reactions.
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
The differences in the study variables of normal, over-
weight and obese individuals were compared with an
ANOVA or Student test for independent samples. Pear-
son’s correlation coefficients were calculated to estimate
the linear correlations between variables and the confi-
dence interval was of 95%. Multiple regression analysis
was used to study which variables were associated with
FASN expression levels. Values were considered to be
statistically significant when P ≤ 0.05. The statistical ana-
lyses and graphics were performed using the program
SPSS (Version 11.5 for Windows; SPSS, Chicago; IL).
Results
The anthropometric and biochemical variables of the
studied subjects and FASN and PPARg gene expression
of the three groups (normal, overweight and obese) are
summarized in Table 1. BMI is directly related to SBP
values (P < 0.01), W-H ratio (P < 0.05), glucose (P <
0.01), HbA1c (P < 0.01), HOMA-IR (P < 0.01), leptin (P
< 0.01) and TG (P < 0.01) levels and inversely related to
FASN expression (P < 0.01) and adiponectin levels (P <
0.01).
Comparisons between normoglycemic and hyperglyce-
mic subjects (Table 2) have shown that the last group
had significantly higher baseline TG readings (P < 0.05),
BMI (P < 0.05), glucose (P < 0.01), HbA1c (P < 0.01)
and HOMA-IR (P < 0.01), and lower levels of FASN
expression (P < 0.01). No significant changes were
detected in the other variables.
Differences according to sex (data not shown) for clin-
ical and laboratory data have shown that leptin and adi-
ponectin levels were significantly higher in females (P <
0.01), the same as CRP (P < 0.05) and HDL-c (P < 0.01).
No differences were found in the rest of variables
between sexes.
The correlation between FASN expression and the dif-
ferent parameters that are associated with diabetes and
obesity have shown the following results: there is a posi-
tive correlation of FASN expression with levels of adipo-
nectin (P < 0.05; r = 0.265; Figure 1a) and HDL-c (P <
0.05; r = 0.276). BMI (P < 0.01; r = 0.383; Figure 1b),
W-H (P < 0.05; r = 0.274), glucose (P < 0.01; r = 0.373),
HOMA-IR (P < 0.01; r = 0.306; Figure 1c), HbA1c (P <
0.01; r = 0.415; Figure 1d) and TG (P < 0.01; r = 0.339)
correlates inversely with FASN expression.
Multiple regression analysis (Table 3) found that
FASN expression levels (as dependent variable) were
related to values of HbA1c (P < 0.01) and BMI (P <
0.01) with a value of the model of R
2 = 0.385 and R
2 =
0.271 respectively. Variables that did not enter in the
model were TG, HDL-c, HOMA-IR, adiponectin and
PPARg1 and PPARg2 (data not shown).
Discussion
We investigated how FASN gene expression in human
a d i p o s et i s s u ei sr e l a t e dt ocarbohydrate metabolism
dysfunctions and obesity. FASN gene expression was
studied in adipose tissue using quantitative RT-PCR in
samples of visceral adipose tissue from 87 volunteers
who varied in terms of BMI, sex and metabolic para-
meters. We used correlation analysis to dissect whether
and to what extent FASN mRNA expression is
explained by the variability in anthropometric and meta-
bolic parameters and we found an inverse correlation of
FASN with Glucose, HOMA-IR, HbA1c, TG, BMI and
Table 2 Anthropometrical and biochemical characteristics
of study subjects: with and without high glycaemia
Patients Control High Glycaemia P
BMI 26.18 ± 4.80 29.51 ± 4.29 0.03
SBP 126.70 ± 18.79 137.75 ± 16.38 0.06
DBP 76.35 ± 10.13 77.50 ± 11.68 0.72
W-H 0.89 ± 0.08 0.91 ± 0.07 0.26
Insulin 12.28 ± 6.29 14.93 ± 8.02 0.20
Glucose 83.78 ± 9.40 136.36 ± 52.61 0.01
HbA1c 5.59 ± 0.38 6.70 ± 0.66 0.00
HOMA-IR 2.56 ± 1.38 5.02 ± 2.50 0.01
Cholesterol 201.43 ± 34.37 194.45 ± 52.35 0.68
TG 105.78 ± 49.68 195.64 ± 113.98 0.03
LDL-c 125.36 ± 26.61 110.91 ± 35.28 0.11
HDL-c 53.81 ± 13.35 49.27 ± 12.10 0.29
CRP 5.75 ± 13.89 3.23 ± 2.58 0.55
Adiponectin 18.94 ± 11.68 14.08 ± 5.68 0.16
Leptin 17.32 ± 17.77 26.83 ± 19.96 0.10
FASN 0.27 ± 0.17 0.08 ± 0.03 0.00
PPARg1 0.07 ± 0.20 0.03 ± 0.03 0.49
PPARg2 0.01 ± 0.00 0.01 ± 0.01 0.98
Values are presented as means ± SD. BMI, body mass index (Kg/m
2); SBP,
systolic blood pressure (mm Hg); DBP, diastolic blood pressure (mm Hg); W-H
ratio, waist to hip ratio; Insulin (UI/ml); Glycaemia (mg/dl); HbA1c, glycated
haemoglobin (%); HOMA-IR, homeostasis model assessment ((gluc mg/dl*insul
U/ml)/405); Cholesterol (mg/dl); TG, triglycerides (mg/dl); LDL-c, low density
lipoprotein-cholesterol (mg/dl); HDL-c, high density lipoprotein-cholesterol
(mg/dl); CRP, c-reactive protein (mg/l); Adiponectin (ng/ml); Leptin (ng/ml);
FASN, fatty acid synthase; PPARg, peroxisome proliferator-activated receptor.
Relationship between variables in control and hyperglycemic individuals was
assessed by Student’s t test.
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ponectin and HDL.
Feeding on simple carbohydrates substantially
increases the activity of FASN, the central enzyme for
de novo synthesis of long-chain saturated FAs [22].
FASN expression and activity are increased by insulin in
cultured human adipocytes, suggesting that insulin sen-
sitivity plays a role in their regulation and is essential in
the uptake of glucose and conversion to TG. Insulin sti-
mulates the transcription of lipogenic genes in rat hepa-
tocytes and adipocytes, and this action has been
confirmed in human adipocytes [23]. The results of the
present study also demonstrate that adipose FASN gene
expression is higher in normoglycemic individuals com-
pared to those with hyperglycaemia, together with lower
values of BMI, TG and obviously glucose, HOMA-IR,
and HbA1c levels in normoglycemics. The relation
between FASN and glycaemia is corroborated by multi-
ple regression analysis where we have demonstrated the
close relation of FASN expression with HbA1c. Due to
the fact that HbA1c is image of medium values of gly-
caemia in the last three months, we took this value as
representative of glycaemia state. This relation is of
more importance when we take into account that what
Figure 1 Linear relationship between FASN expression and adiponectin (a), BMI (b), HOMA-IR (c) and HbA1c (d). Linear relationship was
determined by Pearson’s correlation coefficient test. 95% confidence interval.
Table 3 Multiple regression analysis
Model Nonestandardized
Coefficients
Standardized
Coefficients
tP R
2
B Tip. Error. Beta
1
(Constant) 0.718 0.120 5.980 0.000
0.271
BMI -0.019 0.004 -0.521 -4.182 0.000
2
(Constant) 1.110 0.175 6.353 0.000
0.385 BMI -0.013 0.005 -0.371 -2.936 0.005
HbA1c -0.093 0.032 -0.369 -2.913 0.006
BMI, body mass index (Kg/m
2); W-H, waist to hip ratio; Glucose (mg/dl); HbA1c, glycated haemoglobin (%); HOMA-IR, homeostasis model assessment ((gluc mg/
dl*insul U/ml)/405); TG, triglycerides (mg/dl); LDL-c, low density lipoprotein-cholesterol (mg/dl); HDL-c, high density lipoprotein-cholesterol (mg/dl); Adiponectin
(ng/ml); FASN, fatty acid synthase; PPARg, peroxisome proliferator-activated receptor.
Dependent variable: FASN
Excluded variables: PPARg1, g2, Adiponectin, HOMA-IR, Glucose, TG, HDL-c, W-H
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BMI and metabolic parameters. Moreover, FASN is a
variable that plays a role in body weight regulation and
the development of obesity [13-15]. In this and previous
studies, our laboratory has found that FASN relates
inversely with obesity and th i ss u g g e s t st h a ti tc o u l d
play a role in obesity-associated diabetes.
Our study design also allowed us to investigate the
relationship between FASN mRNA expression and
serum concentrations of adipocytokines (leptin and adi-
ponectin). We found a correlation between FASN and
serum concentrations of adiponectin. These adipocyto-
kines are also BMI dependent in obesity while leptin
increases, adiponectin decreases. According to sex we
can also see that both are present in higher concentra-
tions in women than in men. Leptin could directly sup-
press FASN mRNA expression in adipose tissue, since
experimentally increased plasma leptin concentrations in
rats resulted in a decrease of FASN mRNA levels in fat
[24]. There are data supporting a suppressive action of
leptin on FAS transcription [25]. Adiponectin is an
exclusively adipocyte-derived hormone [26] with a key
role in glucose and lipid metabolism in skeletal muscle
and the liver, acting as an insulin sensitizer [27]. It is
the only adipocytokine known to be down-regulated in
obesity [28] and insulin resistance by decreasing TG
content in muscle and liver [29]. Hypoadiponectinemia
has been more closely related to the degree of insulin
resistance and hyperinsulinemia than the degree of adip-
osity [28].
PPARg has been implicated in almost all aspects of the
cluster of human diseases designated as metabolic syn-
drome [6,7]. Because of this, it is a good candidate to
study, crucial for whole-body insulin sensitivity [30] and
adipogenesis [8]. The actions of PPARg are mediated by
two protein isoforms, the widely expressed PPARg1a n d
the adipose tissue-restricted PPARg2[ 9 ] .P P A R g also
transcriptionally regulates many genes involved in meta-
bolism [12]. But we have found no significant changes
in PPARg1a n dP P A R g2 expression levels related to car-
bohydrate metabolism or FASN expression levels. Our
results do not support the relation of PPARg with FASN
and insulin sensitivity. On the other hand, PPARg acti-
vation is also associated with potentially beneficial
effects on the expression and secretion of adipocyto-
kines [30] which protect nonadipose tissue against lipid
overload. Increased TNFa, leptin, and resistin levels and
decreased adiponectin expression in adipose tissues are
associated with the development of insulin resistance
and vice versa [28,30].
Conclusions
Taken together, it has been demonstrated that FASN is
a candidate gene for the pathophysiology of human
obesity and type II diabetes and we corroborate this
with the correlation of adipose FASN mRNA expression
with several parameters related to obesity and diabetes.
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